Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Change in Accured Expenses (2021 - 2025)

Historic Change in Accured Expenses for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to -$58348.0.

  • InMed Pharmaceuticals' Change in Accured Expenses fell 11622.52% to -$58348.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$299364.0, marking a year-over-year decrease of 45804.81%. This contributed to the annual value of -$249728.0 for FY2025, which is 65149.51% down from last year.
  • Per InMed Pharmaceuticals' latest filing, its Change in Accured Expenses stood at -$58348.0 for Q4 2025, which was down 11622.52% from -$274066.0 recorded in Q3 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Change in Accured Expenses peaked at $765664.0 during Q4 2021, and registered a low of -$642392.0 during Q3 2024.
  • For the 5-year period, InMed Pharmaceuticals' Change in Accured Expenses averaged around -$119721.6, with its median value being -$131800.0 (2022).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first plummeted by 25318.6% in 2023, then surged by 31281.71% in 2024.
  • InMed Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $765664.0 in 2021, then plummeted by 145.66% to -$349611.0 in 2022, then surged by 169.04% to $241378.0 in 2023, then surged by 48.98% to $359614.0 in 2024, then crashed by 116.23% to -$58348.0 in 2025.
  • Its Change in Accured Expenses was -$58348.0 in Q4 2025, compared to -$274066.0 in Q3 2025 and -$5431.0 in Q2 2025.